ALK-001
ALK-001 is in phase II clinical trials for the treatment of Stargardt's disease.
The compound was co-developed by Alkeus Pharmaceuticals and Columbia University.
General Information
Update Date：2016-04-12
- Drug Name：
- ALK-001
- Research Code：
- ALK-001; C20-D3-vitamin A; C20-D3-Retinyl Acetate
- Trade Name：
- MOA：
- Vitamin A analog
- Indication：
- Stargardt’s disease
- Status：
- Phase Ⅱ (Active)
- Company：
- Alkeus (Originator), Columbia University (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-04-12
|
Molecular Weight | 331.51 | ||||||||||||
| Formula | C22H29D3O2 | |||||||||||||
| CAS No. | 118139-36-9 (ALK-001); | |||||||||||||
| Chemical Name | Retin-20,20,20-d3-ol, 15-acetate | |||||||||||||
| ALK-001 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||